Foreign free riders and the high price of US medicines
- 20 October 2005
- Vol. 331 (7522), 958-960
- https://doi.org/10.1136/bmj.331.7522.958
Abstract
The United States government is engaged in a campaign to characterise other industrialised countries as free riding on high US pharmaceutical prices and innovation in new drugs.1 This campaign is based on the argument that lower prices imposed by price controls in other affluent countries do not pay for research and development costs, so that Americans have to pay the research costs through higher prices in order to keep supplying the world with new drugs.1 2 Supporters of the campaign have characterised the situation as a foreign rip-off.3 We can find no evidence to support these and related claims, and we present evidence to the contrary. Furthermore, we explain why the claims themselves contradict the economic nature of the pharmaceutical industry.Keywords
This publication has 4 references indexed in Scilit:
- Pricing medicines: theory and practice, challenges and opportunitiesNature Reviews Drug Discovery, 2005
- Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.2004
- Industrial interests versus public health: the gap is growing.2004
- No Exit and the Organization of Voice in Biotechnology and PharmaceuticalsJournal of Health Politics, Policy and Law, 2003